19 research outputs found

    The GPVI - Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times

    Get PDF
    Glycoprotein VI (GPVI) is a key platelet receptor which mediates plaque-induced platelet activation and consecutive atherothrombosis, but GPVI is also involved in platelet-mediated atheroprogression. Therefore, interference in GPVI-mediated platelet activation has the potential to combine short-term and long-term beneficial effects, specificity and safety especially regarding bleeding complications

    Macroscopic and histological assessment of atherosclerosis in cholesterol-fed rabbits.

    No full text
    <p>(a) Plaque size [%] was determined in macroscopic en face preparations after sudan red staining of the common carotid arteries. The relative lesion area was expressed as percentage of the total vessel area of the common carotid artery. (b) Vessel wet weight to body weight ratio was determined. The mean ± SEM of 8 animals are shown. * indicates significant difference of p<0.05 versus cholesterol-fed atherosclerotic control rabbits.</p

    Effect of systemic delivery of increasing doses of Revacept in rabbits.

    No full text
    <p>Thrombus formation was induced by balloon vascular injury. The thrombus size was evaluated histologically post mortem and is expressed as % of the total vascular lesion area. The mean ± SD of n = 8 experiments per group are shown. * indicates significant difference of p<0.05, and ** of p<0.01, versus controls (as determined by ANOVA).</p

    The inflammation in the arterial wall was assessed by immune-histology in carotid artery sections of cholesterol fed rabbits.

    No full text
    <p>(a) The density of macrophages was determined using specific anti-RAM antibodies.(b) The density of T-lymphatic cells was determined with specific anti CD 4 antibodies. The mean ± SEM of 8 animals are shown.</p
    corecore